Vol. 19/No. 22 | OncologyLive

Triplet Therapy With Novel PD-1 Inhibitor Holds Promise in Melanoma

November 28, 2018

The addition of a novel PD-1 inhibitor to a combination of BRAF inhibitor dabrafenib (Tafinlar) and MEK inhibitor trametinib (Mekinist) is being tested to determine whether the triplet is safe and effective for patients with metastatic or unresectable melanoma.

Novel T-Cell Therapies Make Inroads Into Solid Tumors

November 28, 2018

Although CAR T-cell therapies have proved successful in certain hematologic malignancies, efforts to employ similar strategies in solid tumors have been challenging. Investigators are working on different forms of adoptive cell therapy in solid tumors and early signs are promising.

Combos Pairing Inhibitors of Angiogenesis and Immune Checkpoints Have Potential

November 25, 2018

Therapies that inhibit angiogenesis are attracting fresh interest in combination regimens with immune checkpoint immunotherapy in tumor types such as hepatocellular carcinoma, urothelial carcinoma, and endothelial cancer.

Current and Prospective Therapies Are Improving Outcomes in Relapsed Multiple Myeloma

November 24, 2018

During an OncLive Peer Exchange®, a panel of experts on multiple myeloma discussed new agents and combinations that are improving the care of patients with relapsed multiple myeloma and reviewed strategies for treating these patients when they develop drug resistance.

Roswell Park Transplant Specialists Explore New Strategies for Tackling GVHD

November 24, 2018

Investigators at Roswell Park Comprehensive Cancer Center in Buffalo, New York, are working on a variety of novel approaches, including developing prophylactic drug regimens, studying methods of rejuvenating the recipient’s immune system, and analyzing genetic characteristics to improve donor selection.

Hypofractionated Radiation Recommended for Localized Prostate Cancer

November 20, 2018

A panel of experts has recommended hypofractionated radiation as an alternative to longer, conventional courses of radiation for men with earlystage prostate cancer who opt for external beam radiation therapy.